This paper presents a summary of the evidence review group (ERG) report into the clinical
and cost-effectiveness of erlotinib for the treatment of relapsed non-small cell lung cancer …

OBJECTIVE: A PE analysis was performed to support the reimbursement request of erlotinib
in 2nd/3rd-line treatment of NSCLC in The Netherlands (NL). METHODS: Erlotinib and BSC …

This study was designed to assess the cost-effectiveness of erlotinib compared with
docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …

Background: Erlotinib is proven to prolong survival, delay symptom progression and improve
quality of life for pts with advanced NSCLC (Shepherd et al. N Engl J Med 2005; 353: 123 …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …

Background: Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer,
which is the leading cause of death worldwide with the majority of patients presenting with …

7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …